Pear Therapeutics

Pear (Nasdaq: PEAR) discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

peartherapeutics.com
Boston, MA

CEO: Corey McCann
Arboretum Lead: Tim Petersen

IN THE NEWS

August 3, 2022 in Home Page, News Page, Pear Therapeutics

Pear Therapeutics to Be Added to Russell US Index Series

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that it will be added to the Russell US Index Series in…

December 6, 2021 in Home Page, News Page, Pear Therapeutics

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Company

Pear Therapeutics, Inc. (“Pear Therapeutics”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), recently announced the completion of its business combination with Thimble Point Acquisition…

November 23, 2021 in News Page, Pear Therapeutics

Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), recently announced that it has received Breakthrough Device Designation from the U.S. Food and…

August 10, 2021 in News Page, Pear Therapeutics

Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRX

Pear Therapeutics, Inc. today announced formulary availability of its commercial products at OptumRx, Inc., the innovative pharmacy care services business of Optum, Inc. Pear’s commercial products include the Prescription Digital…